Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873733 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1MAPTMEN1POLB | |
| SCHEMBL5873719 | 0.72 | CCNB2 (0.40) | MAPTFAAHBUB1 | |
| SCHEMBL13244110 | 0.69 | BACE1 (0.42) | SMN1; SMN2ALDH1A1MAPTPOLB | |
| SCHEMBL5873811 | 0.63 | MAP3K11 (0.59) | SMN1; SMN2ALDH1A1MAPTMEN1POLB | |
| SCHEMBL6610170 | 0.63 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5873809 | 0.63 | MAP3K11 (0.59) | SMN1; SMN2ALDH1A1MAPTMEN1POLB | |
| SCHEMBL13244156 | 0.62 | KIT (0.45) | ALDH1A1MAPTMEN1POLBKMT2A | |
| SCHEMBL1971916 | 0.61 | GAA (0.54) | ALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL5873836 | 0.59 | NR1H2 (0.43) | FAAH | |
| SCHEMBL27142810 | 0.59 | MGAM (0.42) | SMN1; SMN2ALDH1A1MEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050282810-A1 | Oxindole derivatives | HARRIS PHILIP A | 2005-12-22 | — | — | US | disclosed |
| US-6964977-B2 | Oxindole derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-15 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030225090-A1 | E.g., 5-(((Z)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-amino)-1,3-dihydro-2H -benzimidazol-2-one; inhibition or antagonism of protein kinases; treating pain or cancer | SMITHKLINE BEECHAM CORPORATION | 2003-12-04 | — | — | US | disclosed |
| EP-1317446-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-11 | — | — | EP | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6498176-B1 | INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS | SMITHKLINEBEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| WO-2002020513-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282810-A1 | Oxindole derivatives | OPRK1, ERBB2, OGFR | SMN1; SMN2 3549/4885ALDH1A1 3635/4885MAPT 3370/4885 |
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | SMN1; SMN2 3527/4885ALDH1A1 3649/4885MAPT 2084/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | SMN1; SMN2 4854/4885ALDH1A1 4171/4885MAPT 2317/4885 |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | SMN1; SMN2 4631/4885ALDH1A1 3290/4885MAPT 4439/4885 |
| US-20030225090-A1 | E.g., 5-(((Z)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-amino)-1,3-dihydro-2H -benzimidazol-2-one; inhibition or antagonism of protein kinases; treating pain or cancer | ERBB2, DSTYK, OPRK1 | SMN1; SMN2 3500/4885ALDH1A1 3801/4885MAPT 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.